Sigma-2 receptor agonist derivatives of 1-Cyclohexyl-4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl]piperazine (PB28) induce cell death via mitochondrial superoxide production and caspase activation in pancreatic cancer

Table 2 Sigma-2 ligands do not induce changes in blood cytology (CBC) following treatment of not tumor-bearing C57BL/6 mice

	Control	PB28	PB221	PB183	PB282	p-value
A.
WBC (10³/μL)	10.58 ± 0.2	11.11 ± 1.97	8.12 ± 0.14	6.42 ± 1.22	5.78 ± 0.78	0.9
RBC (10⁶/μL)	7.14 ± 0.1	10.24 ± 0.3	9.59 ± 0.71	9.24 ± 0.9	9.91 ± 0.31	0.9
HGB (g/dL)	10.7 ± 0.7	15.65 ± 0.55	14.7 ± 0.8	14.85 ± 1.35	15 ± 0.4	0.4
HCT (%)	36.6 ± 0.08	53.4 ± 1.5	50.35 ± 3.75	48.8 ± 3.3	51.1 ± 1.9	0.9
MCV (fL)	51.2 ± 0.32	52.15 ± 0.05	52.5 ± 0.02	52.9 ± 1.6	51.55 ± 0.35	0.6
MCH (pg)	15 ± 0.54	15.3 ± 0.1	15.35 ± 0.35	16.1 ± 0.1	15.15 ± 0.05	0.9
MCHC (%)	29.2 ± 1.21	29.3 ± 0.2	29.25 ± 0.55	30.4 ± 0.7	29.4 ± 0.3	0.9
Platelets (10³/μL)	486 ± 67	643.5 ± 95.5	563 ± 17	727.5 ± 65.5	649.5 ± 167.5	0.5
B.
BUN (mg/dL)	27 ± 0.4	32 ± 1	30.5 ± 3.5	21 ± 2	24.5 ± 0.5	0.9
Creatinine (mg/dL)	0.34 ± 0.02	0.37 ± 0.04	0.35 ± 0.03	0.37 ± 0.04	0.35 ± 0.03	0.9
ALT (μ/L)	260 ± 21	249 ± 9	219 ± 5	203 ± 34	221 ± 63	0.8
AST (μ/L)	5.6 ± 0.05	5.85 ± 0.35	5.35 ± 0.05	5.4 ± 0.5	5.5 ± 0.07	0.7
Total Protein (g/dL)	168 ± 42	194 ± 72	67.5 ± 1.5	197 ± 103	164 ± 52	0.9
Glucose (mg/dL)	62 ± 12.5	92.5 ± 22.5	64.5 ± 7.5	125 ± 55	60 ± 10	0.4

(A) Blood cytology analysis of C57BL/6 mice (n = 3 mice/group) treated with S2L and vehicle (control) for 5 days. The differences in complete blood count laboratory values between the two groups are not statistically significant. (B) Biochemical analysis of C57BL/6 mice (n = 3 mice/group) treated with sigma-2 ligands and vehicle (control) for 5 days. The differences in serum chemistries between the groups are not statistically significant

ISSN: 1471-2407